There is increasing recognition that a minority of bereaved persons experiences persistent and disabling grief symptoms, also termed complicated grief. We review currently proposed criteria for complicated grief in the Diagnostic and Statistical Manual of Mental Disorders (DSM 5) and the International Statistical Classification of Diseases and Related Health Problems (ICD-11), highlight controversies with regard to establishing complicated grief as a psychiatric disorder, summarize recent complicated grief treatment research within a cognitive behavioral treatment framework, and establish a novel and systematic research agenda for complicated grief treatment.
INTRODUCTION
Bereavement is a universal experience and a major life-stressor that is associated with adverse consequences for mental and physical health, including increased mortality [1,2 & ], and substantial societal costs [3] . Although most people recover from a loss without professional help, a minority of bereaved persons across cultures suffers from severe and disabling grief for a prolonged period of time [4] . Various names for this condition have been proposed, such as complicated grief, pathological grief, and prolonged grief disorder, which all have slightly different defining criteria [5] . In the current review, the term 'complicated grief' will be used to describe these disturbed grief patterns. Previous research has investigated complicated grief, its predictors and correlates and has accumulated evidence that complicated grief represents a distinct nosologic and diagnostic entity [4] that requires specific treatments [6 & ,7,8 & ], although it had not been included in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV or the International Statistical Classification of Diseases and Related Health Problems (ICD)-10. The present article reviews proposed diagnostic criteria for complicated grief, highlights some controversies with regard to establishing complicated grief as a psychiatric disorder, and reviews recent research on adult complicated grief treatment to provide concrete recommendations for future research.
NEW DIAGNOSTIC CRITERIA
The DSM 5 conceptualizes complicated grief as a condition for further study named persistent complex bereavement disorder (PCBD) [9] . DSM 5 specifies the following criteria for PCBD: after the death of a close other, the bereaved person experiences clinically relevant and disabling distress for at least 12 months; main symptoms include yearning, emotional pain or preoccupation with the deceased. Additional criteria are reactive distress to the death (e.g., difficulties accepting the death, avoidance of loss reminders) and symptoms indicative of social or identity disruption (e.g., feeling that a part of oneself died with the deceased; difficulty engaging in social activities). Cultural norms should be considered when differentiating normal grief from PCBD. In response to the publication of DSM 5, several PCBD assessment instruments have been developed (e.g., [10, 11] ).
ICD-11 will probably include 'Prolonged Grief Disorder' as a complicated grief diagnosis and classify it as a stress-related disorder [12 & ]. However, diagnostic criteria are likely different from PCBD in the DSM 5, especially the timing criterion: ICD-11 may allow a diagnosis as early as 6 months postloss, if no other normative time frame is established in the bereaved person's cultural or social norms [13] . In spite of the different timing criterion, other main symptoms (yearning and preoccupation) and additional symptoms (anger about the loss, difficulties accepting the death) appear comparable with DSM 5 criteria for PCBD. It remains to be seen whether treatment trials of complicated grief will embrace DSM 5 or ICD-11 criteria and how this will impact the treatment of complicated grief in clinical practice.
GRIEF -NORMAL OR ABNORMAL?
Although the new diagnostic criteria for complicated grief will certainly stimulate research and draw more attention to severe difficulties some people experience after bereavement, efforts to define complicated grief have not been without criticism. The fact that 75% of a culturally diverse lay sample but only 43% of a sample of psychotherapists believe that there are manifestations of grief that can be classified as mental disorders, illustrate that many practitioners are wary of medicalizing a normal response to a major life-stressor [14, 15] . As bereavement is a universally experienced life-event and symptoms of acute grief may be difficult to differentiate from complicated grief based on duration or phenomenology alone ( [5] , but see also [2 & ,16] ), clinicians should indeed be cautious of overdiagnosis. This concern is substantiated by a recent study showing frequent misdiagnosis of prolonged grief disorder based on case descriptions that represent normal grief patterns [17 & ]. Although there is great variability in reactions to bereavement, resulting in different grief trajectories, only a minority of mourners experience persistent high grief levels [18, 19] . Diagnostic concerns are amplified by the DSM 5 removal of the bereavement exclusion for major depression [20, 21] : it is now possible to diagnose a depressive episode at 2 weeks postloss. This may not only pathologize 'normal grievers' but also misclassify persons at risk of developing complicated grief.
Researchers have also critically discussed the frequent changes to diagnostic criteria for complicated grief [22, 23] . The variability in definitions of complicated grief in DSM 5, ICD-11, and previous research could have serious implications for research and practice. For example, the instrument currently most often used to assess complicated grief symptoms in clinical trials, the Inventory of Complicated Grief (ICG) [24] does not correspond entirely with PCBD criteria. Most notably, DSM 5 has introduced new complicated grief symptoms (e.g., difficulty in positive reminiscing; maladaptive self-appraisals) that are not assessed by the ICG. This makes it difficult to establish whether results from previous clinical trials generalize to the treatment of PCBD and may hinder the dissemination of effective treatments into clinical practice.
KEY POINTS
The new criteria for complicated grief proposed in ICD-11 and DSM 5 will stimulate research, but we should be wary of overdiagnosis and misdiagnosis.
Varying diagnostic criteria may negatively impact the comparability of previous and future research and translation of research findings to clinical practice.
Recent trials using CBT techniques demonstrated promising results for comprehensive complicated grief treatments, specific treatment components, and brief online complicated grief treatments. When providing an evaluative review of complicated grief treatment, it is important to consider the full scope of research on grief interventions. The most robust finding in systematic reviews and meta-analyses is that there is no evidence for effects of universal interventions. Treatment generally works best when targeting individuals experiencing marked difficulties adapting to loss (e.g., meeting criteria for complicated grief) [25,26 & ,27]. Caution should be exercised in prescribing medication for complicated grief. Although antidepressants are often prescribed to bereaved persons [28] , older evidence for their effectiveness in reducing complicated grief symptoms is equivocal [29] . Although some studies report positive effects, these studies often do not employ a randomized controlled trial (RCT) design [30] or are otherwise limited in their interpretability (e.g., small sample sizes and large drop-out rates). However, a large placebo-controlled trial of citalopram for complicated grief (in combination with psychotherapy and as stand-alone treatment) has recently been completed [31 && ]. It demonstrates no efficacy of citalopram as stand-alone treatment for complicated grief, but suggests that adding citalopram to an effective CBT treatment may alleviate co-occuring depressive symptoms.
Concerning the effectiveness of psychotherapy in the treatment of complicated grief, systematic reviews show that there is no positive effect for preventive treatments of complicated grief symptom levels ( [26 & ] but see [32] ) and only a small effect for selective interventions for at-risk populations [25] . A recent trial of cognitive behavioral therapy (CBT) interventions for persons bereaved by suicide indeed demonstrated very limited effectiveness [33 & ]. Interventions for persons who meet criteria for complicated grief, however, achieve at least moderate effect sizes postintervention [25,26 & ]. Recent research has also demonstrated that complicated grief is ameliorated more strongly by treatments that are specifically tailored to complicated grief than to interventions that stem from depression treatment such as interpersonal therapy [6 & ,34] . This illustrates the need to further pursue the development and testing of complicated grief specific interventions. One treatment that appears particularly promising is CBT for complicated grief [25,26 & ]. Although various models of complicated grief have been proposed [35, 36] , and general models of coping with bereavement are also useful in understanding complicated grief (e.g., [37] ), we will use a CBT conceptualization of complicated grief [38] to summarize the most recent research within a coherent framework.
COGNITIVE-BEHAVIORAL TREATMENT OF COMPLICATED GRIEF
In brief, the cognitive-behavioral model of complicated grief [38] proposes that three core processes explain the occurrence and persistence of complicated grief symptoms: insufficient integration of the loss with existing autobiographical knowledge [39] ; negative global beliefs (about oneself, the world and the future) and catastrophic misinterpretations of grief symptoms [39] [40] [41] ; and anxious avoidance (i.e., cognitive and overt avoidance of reminders of the loss) [39, 40, [42] [43] [44] [45] [46] and depressive avoidance (i.e., avoidance of social, occupational and recreational activities, and behavioral withdrawal) [39, 41, 44, 47, 48] . Correspondingly, CBT treatments of complicated grief typically consist of creating a coherent, meaningful autobiographical narrative about the loss; challenging negative beliefs and catastrophic misinterpretations through cognitive restructuring; gradually confronting persons with avoided aspects of the loss (e.g., places, objects, memories) through exposure techniques; and/or helping people to set new life-goals and engage in new, meaningful activities [12 & ,37,38]. These techniques were first successfully applied in two seminal studies on CBT in bereaved persons. It was demonstrated that retelling the story about the loss, imaginal and in-vivo exposure, and identifying and working toward new life goals can be effective as part of an integrative complicated grief treatment [34] . Furthermore, cognitive restructuring and tailored exposure exercises effectively reduced complicated grief symptoms, although it may be more beneficial to begin treatment with cognitive restructuring and end it with exposure rather than vice versa [ . For instance, a controlled feasibility study showed that intensive behavioral activation (e.g., self-monitoring of activities, identification of life goals, and engaging in new goal-congruent fulfilling activities) yielded large short-term effects on complicated grief symptom levels [52] . More recently, the literature on CBT treatments for complicated grief has been rapidly expanding; we will highlight three exciting new developments.
First, there is a growth of trials providing stringent tests of comprehensive complicated grief treatments [49,53 & ]. For instance, a 6-week e-mail-delivered tailored exposure treatment resulted in large effects on complicated grief symptom levels relative to a waitlist control group [53 & ]. This is particularly noteworthy, as it may open up future possibilities for staged treatment models, in which brief online treatment is offered as a first option and more intensive psychotherapy is offered only to those still in need of help after this.
WAYS FORWARD: WHAT, HOW, AND FOR WHOM COMPLICATED GRIEF TREATMENTS WORK
Considering that for a long time, most bereavement psychotherapy interventions yielded few beneficial effects [25] , it is a major accomplishment that so many recent CBT treatments target complicated grief effectively. However, even the best treatments only achieve clinically relevant effects in complicated grief for about half or less of all participants, which suggests these treatments can be improved. In order for clients to optimally benefit and for therapists and researchers to be adequately informed, we will highlight important gaps in the complicated grief treatment literature and outline an ambitious research agenda which can be summarized very briefly: we need to establish what, how, and for whom complicated grief treatments work best.
What treatment works best is difficult to determine as results across investigations cannot easily be compared. Psychotherapeutic treatments for complicated grief are heterogeneous in their use of treatment components and are delivered through varying modalities (e.g., internet and face-to-face) and formats (e.g., individual, group, and family). Treatment effectiveness studies also commonly differ in other respects, including complicated grief diagnostic criteria and treatment outcome assessment. Furthermore, trials often test the short-term effectiveness of novel therapies in relatively small samples, leading to a patchwork of preliminary evidence rather than a broad evidentiary base for a few clearly defined treatments (but see [6 & ,49,50 & ]). Generalizability of results may also be limited as samples predominantly comprise higher educated female adults from Western countries ( [26 & ], but see [47, 54] ).
To establish what works when treating complicated grief, future research should aim at programmatically and systematically assessing short-term and long-term effects of existing treatments showing promising effects using adequately powered multicenter RCTs. The work of Shear et al.
& ,34] can be considered exemplary, as it first evaluated the effectiveness of a complicated grief treatment in a small initial RCT, replicated results in a larger sample, and a multicenter trial was recently completed [31 && ]. Furthermore, it should be investigated whether trial results generalize across samples with lower education and more men, children and adolescents, and people with non-Western cultural backgrounds. Particular attention should be directed to the independent replication of research findings as this is rarely done, but it constitutes a key criterion for the establishment of evidence-based treatments [55] . In addition, dismantling studies comparing the effects of different treatment components (e.g., [7,53 & ]) or effects of adding components to a more comprehensive treatment (e.g., [8 & ]) can provide information on which treatment elements are most efficacious. Simultaneously, new promising approaches should be tested (e.g., [56, 57] ), ideally against proven-effective treatments, to benefit optimally from the creativity of researchers and clinicians.
How complicated grief treatments work can be elucidated using two main methods. On the one hand, the theoretical basis for complicated grief treatment should be clarified further to improve our understanding of how complicated grief can best be targeted. For example, although studies have shown that exposure to the loss can be highly effective in treating complicated grief [7,8 & ,53 & ], evidence of the association between loss avoidance and complicated grief is mixed. Surveys generally show positive associations between both constructs [39] [40] [41] [42] 44, 48] , but laboratory investigations have shown conflicting results, sometimes yielding positive associations between complicated grief and attention for loss-related cues [58] , and sometimes none [45, 59] . On the other hand, mediators of treatment effects should be examined, to ascertain what processes explain treatment effects, so that these mechanisms of change can be targeted more effectively in complicated grief treatment. Mediation analyses are surprisingly rare, with no mediation analyses of complicated grief treatment trials published to date, although treatment effects on negative cognitions and avoidance processes have been found to be associated with CBT treatment effects on complicated grief [60] .
It also needs to be investigated for whom complicated grief treatment yields the best results, to establish whether specific treatments need to be developed for certain subpopulations. An older meta-analysis showed that no variables other than distress levels consistently moderate treatment effects of grief interventions [25] , and the effectiveness of complicated grief treatments clearly illustrates this point. Few researchers have attempted to further elucidate for whom complicated grief treatment works best since this review. However, one trial demonstrated that recently suicide-bereaved persons with high suicide ideation showed larger reductions in complicated grief symptoms in response to CBT treatment than those with low suicide ideation [61] . This seems to imply that no specific treatments need to be developed for persons with suicidal thoughts (as long as no acute suicidal tendencies exists), but more research is indicated to draw firm conclusions.
CONCLUSION
In summary, the diagnostic criteria as proposed in ICD-11 and DSM 5, though critically discussed by researchers and clinicians, will draw increased attention to the treatment of complicated grief. It remains of utmost importance to avoid both overdiagnosis and misdiagnosis of complicated grief. Although recent research convincingly demonstrates that psychological treatments (in particular CBT) are effective in treating complicated grief, there are still many remaining questions. This review introduces a systematic research agenda to answer these questions: we recommend conducting both theoretically focused studies and clinical trials in large, heterogeneous bereaved samples, to establish what treatment (components) are most effective for whom and how these treatments work. This would create a broad evidentiary base for treatments that could inform clinicians and researchers and optimally benefit bereaved persons in need of help. In light of the encouraging evidence that has accumulated during the period covered by this review, this goal now seems more feasible than ever. 
